C57BL/6JCya-Gins2em1flox/Cya
Common Name:
Gins2-flox
Product ID:
S-CKO-09981
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Gins2-flox
Strain ID
CKOCMP-272551-Gins2-B6J-VA
Gene Name
Product ID
S-CKO-09981
Gene Alias
2210013I18Rik; 4833427B12Rik; Pfs2; Psf2
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
8
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Gins2em1flox/Cya mice (Catalog S-CKO-09981) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000034278
NCBI RefSeq
NM_178856
Target Region
Exon 3
Size of Effective Region
~1.1 kb
Detailed Document
Overview of Gene Research
GINS2, a subunit of DNA helicase, is crucial for maintaining genomic stability as it contributes to DNA replication processes [2,5]. It is involved in various signaling pathways, such as STAT3/MYC, EGR1/ECT2, PTP4A1/p53, ERK/MAPK, PI3K/Akt, and STAT, influencing cell growth, apoptosis, and epithelial-mesenchymal transition (EMT) in different biological contexts [1,2,3,4,7,8].
GINS2 is highly expressed in several cancers including osteosarcoma, gliomas, colon cancer, pancreatic cancer, HNSCC, and NSCLC, promoting tumorigenesis, cell proliferation, and inhibiting apoptosis. For example, in osteosarcoma, GINS2 knockdown hindered cell growth and induced apoptosis both in vitro and in vivo, and reduced the activity of the MYC signaling pathway [1]. In gliomas, GINS2 regulated temozolomide chemosensitivity via the EGR1/ECT2 axis [2]. In colon cancer, GINS2 knockdown inhibited cell proliferation and increased apoptosis through the PTP4A1/p53 pathway [3]. In pancreatic cancer, GINS2 promoted EMT via the ERK/MAPK signaling pathway [4]. In HNSCC, GINS2 promoted cell proliferation and inhibited apoptosis by altering RRM2 expression [6]. In NSCLC, GINS2 promoted cell proliferation, migration, invasion, and EMT via the PI3K/Akt and MEK/ERK signaling pathways [7]. In contrast, in lung cancer, GINS2 knockdown inhibited cell proliferation, suggesting it may act as a tumor suppressor through the STAT signaling pathway [8]. Also, in intervertebral disk degeneration, GINS2 was downregulated in the peripheral blood, and overexpressing it promoted the proliferation and migration of nucleus pulposus cells [9]. In hepatocellular carcinoma, GINS2-overexpressed patients had poorer survival, and it was associated with cell cycle, DNA replication, and immune cell infiltration [10].
In conclusion, GINS2 plays diverse roles in different biological processes and diseases. Its overexpression in many cancers promotes tumor-related phenotypes, while in some cases like lung cancer, it may have a tumor-suppressive role. The study of GINS2 through gene-knockout or conditional-knockout models in mice (although not specifically detailed in the references but a valuable approach in general) could further clarify its functions and mechanisms in these disease areas, potentially providing new therapeutic targets for cancer and other diseases.
References:
1. Ren, Bingkai, Zheng, Yibin, Nie, Lizhong, Wei, Jingdu, Yang, Dong. 2023. GINS2 Promotes Osteosarcoma Tumorigenesis via STAT3/MYC Axis. In Journal of oncology, 2023, 8454142. doi:10.1155/2023/8454142. https://pubmed.ncbi.nlm.nih.gov/36873736/
2. He, Hua, Liang, Lu, Jiang, Shiyao, Jiang, Yiqun, Cong, Li. 2024. GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas. In Cell death & disease, 15, 205. doi:10.1038/s41419-024-06586-w. https://pubmed.ncbi.nlm.nih.gov/38467631/
3. Hu, Hao, Ye, Lina, Liu, Zhe. 2022. GINS2 regulates the proliferation and apoptosis of colon cancer cells through PTP4A1. In Molecular medicine reports, 25, . doi:10.3892/mmr.2022.12633. https://pubmed.ncbi.nlm.nih.gov/35137928/
4. Huang, Longping, Chen, Si, Fan, Haijun, Chen, Chuanping, Sheng, Weiwei. 2020. GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling. In Cancer gene therapy, 28, 839-849. doi:10.1038/s41417-020-0206-7. https://pubmed.ncbi.nlm.nih.gov/32747685/
5. Nabais Sá, Maria J, Miller, Kerry A, McQuaid, Mary, de Brouwer, Arjan P M, Oliveira, Jorge. 2021. Biallelic GINS2 variant p.(Arg114Leu) causes Meier-Gorlin syndrome with craniosynostosis. In Journal of medical genetics, 59, 776-780. doi:10.1136/jmedgenet-2020-107572. https://pubmed.ncbi.nlm.nih.gov/34353863/
6. Wang, Tianxiang, Qian, Luxi, Zhang, Pingchuan, Yin, Li, He, Xia. . GINS2 promotes the progression of human HNSCC by altering RRM2 expression. In Cancer biomarkers : section A of Disease markers, 40, 171-184. doi:10.3233/CBM-230337. https://pubmed.ncbi.nlm.nih.gov/38517779/
7. Liu, Xiangli, Sun, Lei, Zhang, Song, Zhang, Shuguang, Li, Wenya. 2019. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling. In Journal of cellular physiology, 235, 7747-7756. doi:10.1002/jcp.29381. https://pubmed.ncbi.nlm.nih.gov/31681988/
8. Sun, Dianmin, Zong, Yuanyuan, Cheng, Jinling, Xing, Ligang, Yu, Jinming. 2021. GINS2 attenuates the development of lung cancer by inhibiting the STAT signaling pathway. In Journal of Cancer, 12, 99-110. doi:10.7150/jca.46744. https://pubmed.ncbi.nlm.nih.gov/33391406/
9. Jiang, Haitao, Sun, Hailang, Dai, Jian, Zhang, Cheng, Tang, Xiaoming. 2022. GINS2 Is Downregulated in Peripheral Blood of Patients with Intervertebral Disk Degeneration and Promotes Proliferation and Migration of Nucleus Pulposus Cells. In Computational and mathematical methods in medicine, 2022, 1986348. doi:10.1155/2022/1986348. https://pubmed.ncbi.nlm.nih.gov/36092790/
10. Li, Zuyin, Song, Guohe, Guo, Dezhen, Wang, Xiaoliang, Wang, Yupeng. 2022. Identification of GINS2 prognostic potential and involvement in immune cell infiltration in hepatocellular carcinoma. In Journal of Cancer, 13, 610-622. doi:10.7150/jca.53841. https://pubmed.ncbi.nlm.nih.gov/35069907/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen